BenevolentAI's platform found a novel IPF target that AstraZeneca selected for its portfolio.
IPF is a fatal lung scarring disease with unclear cause and limited treatment. BenevolentAI scientists worked with AstraZeneca using its AI platform and biomedical knowledge graph to identify targets for IPF and chronic kidney disease. Two novel targets were selected, the IPF one by December 2021, and the collaboration won a Scrip Award.
BenevolentAI is a UK AI drug discovery company whose platform and biomedical knowledge graph are used for target identification with pharma partners such as AstraZeneca.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Published by BenevolentAI on its own site — read the original case study on benevolent.com ↗
Related use cases
- 01OpenAI's dedicated healthcare vertical page/launch post.
- 02Frontier reasoning model built for biology, drug discovery and translational medicine; named qualified customers include Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.
- 03follow-up update to the life-sciences model.
- 04"How Amgen uses GPT-5": Amgen applies GPT-5/frontier models to help accelerate delivery of potential new therapies; found GPT-5 met scientific-accuracy standards.
- 05Moderna and OpenAI partner to accelerate development of treatments; ChatGPT Enterprise deployed to thousands of employees company-wide.
- 06Longevity biotech collaborated with OpenAI to build and research GPT-4b micro, a version of GPT-4o specialized for protein engineering.